DLA Piper advises Agilent Technologies, Inc. in its acquisition of BioVectra for US$925 million

DLA Piper advised Agilent Technologies, Inc. (Agilent), a global leader in life sciences, diagnostics and applied chemical markets, in connection with its proposed acquisition of BioVectra, a contract drug manufacturer, for US$925 million.

Based in Canada, BioVectra produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics, and supports early-stage clinical development to large-scale commercial manufacturing.

The DLA Piper corporate deal team was led by partners Eric Wang and Philipp Tsukanov (both in Palo Alto) and Catherine Gibson (Vancouver) and included associates Jaspreet K. Mann (San Francisco), Kaleigh Nevin (Vancouver) and Gina Cassar (Palo Alto).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 14 consecutive years, according to Mergermarket, and ranked as a top five most active VC legal advisor in the US and number one in VC, PE and M&A in combined global deal volume according to PitchBook.

DLA Piper’s globally recognized life sciences team has spent decades helping entrepreneurs, companies, innovators, and investors turn their most promising and disruptive ideas into successful businesses. Drawing on diverse backgrounds in the legal, financial, and medical sectors and beyond, our team brings a distinctive blend of experience to develop client-focused solutions. We understand the unique challenges life science companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new paths to profitability, and protecting existing innovation. Our approach delivers both strategic and practical counsel to clients, ultimately leading to better human outcomes.